Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. It is available in oral and intravenous formulations.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Maintenance of healing of erosive esophagitis
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Peptic ulcer disease (PUD)
* H. pylori eradication (in combination with antibiotics)
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or IV once daily for 7 to 8 weeks.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily. Doses of 20 mg orally once daily may be sufficient for some patients.
* **Pathological hypersecretory conditions:** 40 mg orally or IV twice daily. Doses may be increased as clinically needed. Maximum recommended dose is 120 mg IV every 8 hours or 240 mg IV once daily.
* **H. pylori eradication:** 40 mg orally twice daily for 7 to 14 days in combination with clarithromycin and amoxicillin, or clarithromycin and metronidazole.
* **Stress ulcer prophylaxis:** 40 mg orally or IV once daily.
## Pediatric Dosing
Dosing in pediatric patients is complex and often requires specific protocol guidance.
* **Erosive esophagitis (age 5 to 16 years):**
* 20 mg orally once daily for up to 8 weeks.
* 40 mg orally once daily for up to 8 weeks for patients not healed on 20 mg.
* **GERD (age 5 to 16 years):**
* 20 mg orally once daily for up to 8 weeks.
*Note: Intravenous administration in pediatric patients is generally limited to specific situations and may follow weight-based protocols not universally established.*
## Dose Adjustments
* **Hepatic Impairment:** Maximum oral dose of 40 mg once daily. IV dose should not exceed 40 mg once daily.
* **Renal Impairment:** No dose adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Use in patients receiving rilpivirine-containing antiretroviral therapies.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use may be associated with an increased risk of bone fractures, Clostridium difficile infection, hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Clopidogrel:** Pantoprazole may decrease the antiplatelet effect of clopidogrel. Consider alternatives if possible, or monitor closely.
* **Antiretrovirals (e.g., rilpivirine, atazanavir):** PPIs can decrease absorption of certain antiretrovirals due to increased gastric pH.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **Drugs dependent on gastric pH for absorption (e.g., ketoconazole, itraconazole, iron salts):** Absorption may be decreased.
## Monitoring
* Monitor for signs and symptoms of Clostridium difficile infection.
* Monitor magnesium levels, especially in patients on long-term therapy or receiving concomitant diuretic therapy.
* Monitor for signs of fracture if long-term use is indicated.
* For H. pylori eradication, ensure completion of antibiotic regimen.
## Clinical Pearls
* Oral pantoprazole is generally taken 30-60 minutes before a meal.
* IV pantoprazole should be administered as an infusion over 15 minutes or infused over 2 minutes.
* Do not crush or chew delayed-release oral formulations.
* For GERD symptom relief, once healing is achieved, a step-down therapy to 20 mg daily or on-demand therapy may be considered.
* Long-term PPI use should be periodically reassessed to determine the need for continued therapy.
---
***Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions. Dosing may vary based on individual patient factors and institutional protocols.*
